Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Relationship between low LDL cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US observational study using electronic medical records

ABSTRACT: Relationship between low LDL cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US observational study using electronic medical records

PROVIDER: PRJNA454348 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

electronic Medical Records & Genomics (eMERGE)

Project description:electronic Medical Records & Genomics (eMERGE)

| PRJNA158491 | ENA

Relationship between low LDL cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US observational study using electronic medical records

Project description:Relationship between low LDL cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US observational study using electronic medical records

| PRJNA454347 | ENA

High-throughput genetic analyses of drug intolerances using electronic health records

Project description:High-throughput genetic analyses of drug intolerances using electronic health records

| PRJNA683675 | ENA

Characterization of statin dose response in electronic medical records.

Project description:Efforts to define the genetic architecture underlying variable statin response have met with limited success, possibly because previous studies were limited to effect based on a single dose. We leveraged electronic medical records (EMRs) to extract potency (ED50) and efficacy (Emax) of statin dose-response curves and tested them for association with 144 preselected variants. Two large biobanks were used to construct dose-response curves for 2,026 and 2,252 subjects on simvastatin and atorvastatin, respectively. Atorvastatin was more efficacious, was more potent, and demonstrated less interindividual variability than simvastatin. A pharmacodynamic variant emerging from randomized trials (PRDM16) was associated with Emax for both. For atorvastatin, Emax was 51.7?mg/dl in subjects homozygous for the minor allele vs. 75.0?mg/dl for those homozygous for the major allele. We also identified several loci associated with ED50. The extraction of rigorously defined traits from EMRs for pharmacogenetic studies represents a promising approach to further understand the genetic factors contributing to drug response.

| S-EPMC3944214 | biostudies-literature

Vanderbilt Genome-Electronic Records (VGER) Project: QRS Duration

Project description:An important potential enabling resource for Personalized Medicine is the combination of a DNA repository with Electronic Medical Record (EMR) systems sufficiently robust to provide excellence in clinical care and to serve as resources for analysis of disease susceptibility and therapeutic outcomes across patient populations. The Vanderbilt EMR is a state of the art clinical and research tool (that includes >1.7 million records), and is associated with a DNA repository which has been in development for over 3 years; these are the key components of VGER, the Vanderbilt Genome-Electronic Records project, a part of NHGRI's eMERGE network. The VGER model acquires DNA from discarded blood samples collected from routine patient care, and can link these to de-identified data extracted and readily updated from the EMR. The phenotype we analyze here is the QRS duration on the electrocardiogram, since slow conduction (indicated by longer QRS duration) is a marker of arrhythmia susceptibility.

| phs000188.v1.p1 | EGA

Electronic cigarettes

Project description:Electronic cigarettes

| PRJNA485536 | ENA

Statin-induced Myopathy

Project description:We performed a genome-wide association study in pooled DNA samples from patients with severe statin myopathy and persistent symptoms post-therapy versus pooled DNAs from an age-adjusted statin-tolerant group. Affymetrix 100K SNP arrays were used according to the manufacturers instructions with two pools of 19 and 20 statin myopathy patients and two pools of 20 statin-tolerant controls.

2010-07-09 | E-GEOD-17574 | biostudies-arrayexpress

Low LDL Cholesterol and Increased Risk of Type 2 Diabetes

Project description:Lipid lowering therapy using HMG-CoA reductase inhibitors (statins) is associated with an approximately 9-12% increase in the risk of new-onset type 2 diabetes (T2DM). The risk of diabetes could be increased by statins directly; however, genetic approaches have also implicated low LDL cholesterol (LDL-C) concentrations as a risk factor for T2DM. Mendelian randomization studies using functional variants in both HMGCR (<a href="https://www.ncbi.nlm.nih.gov/gene/?term=HMGCR" target="_blank">GeneID:3156</a>) and PCSK9 (<a href="https://www.ncbi.nlm.nih.gov/gene/?term=PCSK9" target="_blank">GeneID:255738</a>) genes found a higher risk of T2DM in individuals with variants associated with lower LDL-C concentrations. Since PCSK9 and HMGCR are involved in lipid metabolism through distinct molecular pathways, the altered glycemic effect associated with variants in both genes is likely to be the result of their common effect on LDL-C concentrations. Despite the findings from statin clinical trials and genetic studies, there is little direct evidence implicating low LDL-C concentrations with increased risk of T2DM. Individuals who have very low LDL-C concentrations not due to lipid lowering therapy can provide insights into the relationship between low LDL-C concentrations and T2DM. Here, we used de-identified electronic health records (EHRs) to test the hypothesis that low LDL-C concentrations are associated with T2DM.

| phs001588 | dbGaP

Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer

Project description:RATIONALE: Use of a web-based risk assessment tool may help improve screening rates for colorectal cancer. PURPOSE: This randomized clinical trial is studying personal electronic health records to see how well they work in improving screening rates for colorectal cancer.

| 2082240 | ecrin-mdr-crc

Statin-induced Myopathy

2010-07-09 | GSE17574 | GEO